Yi-Jiun Lin

Open AccessArticle by Yun-Da Li 1,2,3, Ming-Kai Hsieh 2, De-Mei Lee 4, Yi-Jiun Lin 1, Tsung-Ting Tsai 2, Po-Liang Lai 2,* and Ching-Lung Tai 1,2,* 1 Department of Biomedical Engineering, Chang Gung University, Taoyuan 333, Taiwan 2 Department of Orthopedic Surgery, Spine Section, Bone and Joint Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan 3 Department of Orthopedic Surgery, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New...

Abstract Background This was a phase 1, dose-escalation open-label trial to evaluate the safety and immunogenicity of MVC COV1901, a SARS-CoV-2 S-2P protein vaccine adjuvanted with aluminum hydroxide and CpG 1018. Methods Between September 28 and November 13 2020, 77 participants were screened. Of these, 45 healthy adults from 20 to 49 years of age were to be administered two doses of MVC COV1901 in doses of 5 μg, 15 μg, or 25 μg of spike protein at 28 days apart.